Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

26 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Parlodel Articles

Reassuring CV safety from Ph IIIb Cycloset trial

2 July 2007

UK NHS to offer free IVF treatment

1 March 2004

J&J To Cut 4,100 Jobs, Taking $800 Million Charge

8 December 1998

Stock Commentary New York

3 December 1998

Bromocriptine For Obesity

29 July 1998

Preclinical Data Provide Support For Ergoset

18 June 1998

J&J Hooks Up With Ergo For Bromocriptine

25 February 1998

French Reimbursable Delistings

18 December 1997

Novartis Pipeline: A Good Fit But Cuts Are Expected

18 March 1996

Novartis Pipeline: A Good Fit But Cuts Are Expected

18 March 1996

Sandoz To License Orion Parkinson's Drug

4 March 1996

P&U Files In USA For Parkinson's Drug

15 January 1996

Novel Drugs Will Drive Euro Anti-Parkinson's Market

27 November 1995

Ergo Science Learns From Natural Metabolic Patterns

19 June 1995

Sandoz's Parloel and Zaditen in France

12 June 1995

Sandoz pralodol

15 May 1995

IFPMA Marketing Code Violation Publicized

20 February 1995

Sandoz Hong Kong In Talks Over Parlodel

19 September 1994

Sandoz Stops Parlodel Anti-Lactation Sales

5 September 1994

Sandoz Faces Parlodel Lawsuits In USA

22 August 1994

BROMOCRIPTINE SUSPENSION IN USA?

4 October 1993

ARES-SERONO PIPELINE OVERVIEW

31 May 1993

WORLD CNS MARKET IS LARGE AND FRAGMENTED

22 February 1993

NEW APPROACHES IN TREATING PARKINSONISM

7 December 1992

Showing 1-24 of 24 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Proposal to list Roche's Neulastim and Actemra in New Zealand
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Proposal to list Roche's Neulastim and Actemra in New Zealand
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS